Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors?

Diabetes: Metformin — a cardiovascular moderator of DPP4 inhibitors?, Published online: 24 November 2017; doi:10.1038/nrendo.2017.154

Three cardiovascular outcome trials failed to show superiority of DPP4 inhibitors compared with placebo in patients with type 2 diabetes mellitus and high cardiovascular risk, a rather disappointing finding. Now, a post hoc subgroup analysis suggests that patients treated with metformin at baseline might benefit from DPP4 inhibitors in contrast with metformin non-users.

中文翻译：

---

糖尿病：二甲双胍-DPP4抑制剂的心血管调节剂？

糖尿病：二甲双胍-DPP4抑制剂的心血管调节剂？

糖尿病：二甲双胍-DPP4抑制剂的心血管调节剂？，在线发布：2017年11月24日；doi：10.1038 / nrendo.2017.154

两项心血管结局试验未能显示DPP4抑制剂在2型糖尿病和高心血管风险患者中优于安慰剂，这一发现令人失望。现在，事后亚组分析表明，与未使用二甲双胍的患者相比，在基线时接受二甲双胍治疗的患者可能会受益于DPP4抑制剂。